Zacks is out with a $65 price target on Abbott labs. From the article:
"Abbott also possesses a lower risk profile than smaller players in the industry. Although the stock remains one of the more expensive names in the large-cap pharma space, we feel it’s well deserved. We believe, based on Abbott’s very strong line-up of current products -- along with its formidable pipeline -- that there’s further room for the multiple to expand."